Considerations of safety for women prescribed apixaban or rivaroxaban who breastfeed—a physiologically based pharmacokinetic analysis
Journal of Thrombosis and Haemostasis · 2026
DOI: 10.1016/j.jtha.2025.09.040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026. Verfasst von Andrew S Butler und 3 weiteren Autor:innen. Beteiligte Einrichtung: Medicines & Healthcare Products Regulatory Agency, London, UK. Hauptthemen laut MEDLINE: Rivaroxaban, Pyrazoles, Pyridones, Breast Feeding. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bill and Melinda Gates Foundation.
Abstract (Originalsprache)
BACKGROUND: The risk of venous thromboembolism is significantly increased during the perinatal period. The safety of the direct oral anticoagulants, apixaban and rivaroxaban, has not been established in women who breastfeed. Physiologically based pharmacokinetic (PBPK) modeling provides a means to understand drug disposition and is increasingly being used to predict infant exposure to maternal medication via breastmilk. OBJECTIVES: To utilize established PBPK models of apixaban and rivaroxaban to simulate infant exposure to maternal ingestion. METHODS: Existing PBPK models for apixaban and rivaroxaban were adapted to the lactation setting. These models were verified using published reports of apixaban and rivaroxaban from breastfeeding women. A virtual postpartum population was then generated to simulate maternal and infant exposure to rivaroxaban and apixaban at different doses and time points during the postpartum period. Work was conducted on Simcyp Simulator (v23). RESULTS: The adapted apixaban and rivaroxaban PBPK models captured the published breastfeeding clinical data well. Apixaban transferred into human breastmilk significantly more than rivaroxaban. Steady state infant plasma AUC24-48 to a fully breastfed infant following maternal dose of rivaroxaban 20 mg daily was 242 (±107) ng/mL·h in the immediate postpartum period and for apixaban 5 mg twice a day AUC24-48 was 2041 (±466) ng/mL. Maternal exposure to apixaban and rivaroxaban was lower immediately postdelivery and then normalized by 6 weeks postpartum. CONCLUSION: Our work demonstrates that apixaban would not be a suitable agent for breastfeeding women during the postnatal period, while rivaroxaban shows significant promise due to low infant exposure and warrants further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medicines & Healthcare Products Regulatory Agency, London, UK.
- King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital Foundation National Health Service Trust, London, UK. Electronic address: https://x.com/AryaRoopen.
- King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital Foundation National Health Service Trust, London, UK; Institute of Pharmaceutical Science, Faculty of Life Sciences and Medicine,…
Förderung
- Bill and Melinda Gates Foundation
Zitieren
APA
Butler, A. S., Cole, S., Arya, R., & Patel, J. P. (2026). Considerations of safety for women prescribed apixaban or rivaroxaban who breastfeed—a physiologically based pharmacokinetic analysis. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2025.09.040
Vancouver
Butler AS, Cole S, Arya R, Patel JP. Considerations of safety for women prescribed apixaban or rivaroxaban who breastfeed—a physiologically based pharmacokinetic analysis. Journal of Thrombosis and Haemostasis. 2026. doi:10.1016/j.jtha.2025.09.040
BibTeX
@article{Butler2026,
author = {Butler, Andrew S and Cole, Susan and Arya, Roopen and Patel, Jignesh P},
title = {Considerations of safety for women prescribed apixaban or rivaroxaban who breastfeed—a physiologically based pharmacokinetic analysis},
journal = {Journal of Thrombosis and Haemostasis},
year = {2026},
doi = {10.1016/j.jtha.2025.09.040}
}
EUVIMED